Ironwood Pharmaceuticals, Inc. $IRWD Stock: Ritholtz Wealth Management Grows Stake

Ritholtz Wealth Management raised its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) by 130.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 831,091 shares of the biotechnology company’s stock after purchasing an additional 470,997 shares during the quarter. Ritholtz Wealth Management owned 0.50% of Ironwood Pharmaceuticals worth $3,299,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Ironwood Pharmaceuticals by 724.5% in the first quarter. Arrowstreet Capital Limited Partnership now owns 3,397,242 shares of the biotechnology company’s stock worth $11,924,000 after buying an additional 2,985,181 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Ironwood Pharmaceuticals by 529.3% during the first quarter. Dimensional Fund Advisors LP now owns 2,082,055 shares of the biotechnology company’s stock valued at $7,307,000 after buying an additional 1,751,219 shares during the last quarter. Pacer Advisors Inc. purchased a new stake in Ironwood Pharmaceuticals during the first quarter valued at approximately $3,982,000. Sei Investments Co. raised its position in Ironwood Pharmaceuticals by 10.2% in the first quarter. Sei Investments Co. now owns 742,548 shares of the biotechnology company’s stock worth $2,606,000 after acquiring an additional 68,686 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in Ironwood Pharmaceuticals in the second quarter worth approximately $2,142,000.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Jefferies Financial Group upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a research note on Friday, September 25th. Zacks Research cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Weiss Ratings raised Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Finally, Wall Street Zen upgraded Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.23.

Read Our Latest Report on IRWD

Ironwood Pharmaceuticals Price Performance

Shares of IRWD stock opened at $4.83 on Monday. Ironwood Pharmaceuticals, Inc. has a one year low of $2.95 and a one year high of $5.78. The company’s fifty day moving average price is $3.97 and its 200-day moving average price is $3.96. The company has a market capitalization of $799.61 million, a price-to-earnings ratio of 5.37 and a beta of 0.25.

Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last issued its earnings results on Thursday, November 5th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.04. Ironwood Pharmaceuticals had a net margin of 37.38% and a negative return on equity of 81.40%. The company had revenue of $133.04 million during the quarter, compared to the consensus estimate of $119.99 million. Equities research analysts expect that Ironwood Pharmaceuticals, Inc. will post 1.10 earnings per share for the current fiscal year.

About Ironwood Pharmaceuticals

(Free Report)

Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing treatments for gastrointestinal diseases. Founded in 1998, the company is headquartered in Boston, Massachusetts. Its principal product is LINZESS (linaclotide), a prescription medicine for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. Ironwood and AbbVie collaborate on the product’s U.S. commercialization, while licensing partners make linaclotide available in other markets under regional brand names.

Featured Stories

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.